Test description
Testing for genetic variantsin BRCA1 and BRCA2 is used to determine eligibility for PARP inhibitor therapy in relapsed high grade serous ovariancancer, metastatic castration-resistant prostate cancer, and breast cancer.
Test information
BRAoVOTM Rx Gene panel
Used to:
Determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme (PBS), in a patient with:
(a) advanced (FIGO III‑IV) high‑grade serous or high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer; or
(b) breast cancer; or
(c) metastatic castration‑resistant prostate cancer.
BRCA1, BRCA2
Massively Parallel Sequencing
4 - 5 weeks
$499 if patient is not Medicare eligible
Cancer genetics request form preferred. Standard pathology request form accepted.
Blood x 2
EDTA tube
2 x Bloods taken at 10 minute intervals. Pre-test genetic counselling required. Patient to provide consent prior to testing.